Skip to main content
SpringerLink
Log in

Lincomycin and clindamycin: Their role in chemotherapy of anaerobic and microaerophilic infections

Lincomycin und Clindamycin: Ihre Bedeutung in der Behandlung von anaeroben und mikroaerophilen Infektionen

  • Übersicht
  • Published:
Infection Aims and scope Submit manuscript

Summary

Lincomycin is active against the following anaerobic organisms: anaerobic gram-negative bacilli such as Bacteroides species and Fusobacterium species; anaerobic gram-positive nonspore-forming bacilli such as Propionibacterium, Eubacterium, and Actinomyces species; anaerobic and microaerophilic gram-positive cocci such as Peptococcus species, Peptostreptococcus species and microaerophilic streptococci; and Clostridium species. Clindamycin, 7(S)-chloro, 7-deoxylincomycin is four to eight times as active as lincomycin in vitro, against the above mentioned anaerobes. Clindamycin is available in oral dosage forms and is just now being made available as clindamycin phosphate, a new injectable form of clindamycin.

Zusammenfassung

Lincomycin ist wirksam gegen folgende anaerobe Mikrooarganismen: Bacteroides-Spezies und Fusobacterium-Spezies; anaerobe nicht-sporenbildende gram-positive Keime, wie Propionibacterium, Eubacterium und Actinomyces-Spezies; ferner anaerobe und mikroaerophile gram-positive Kokken, wie z. B. Peptoccocus-Spezies, Peptostreptococcus-Spezies und mikroaerophile Streptokokken sowie Clostridien. Clindamycin, 7(S)-Chloro, 7-Deoxylincomycin ist in vitro 4–8mal aktiver als Lincomycin gegenüber den oben erwähnten Anaerobiern. Es ist in oraler Applikationsform im Handel und nun auch als Clindamycin-Phosphat für parenterale Applikation in den USA verfügbar.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ingham, H. R., Selkon, J. B., Codd, A. A., Hale, J. H. The Effect of Carbon Dioxide on the Sensitivity of Bacteroides fragilis to Certain Antibiotics in vitro, J. Clin. Path. 23 (1970) 254–258.

    Google Scholar 

  2. Bartlett, J. G., Sutter, V. L., Finegold, S. M. Treatment of Anaerobic Infections with Lincomycin and Clindamycin, New Eng. J. of Med. 287 (1972) 1006–1010.

    Google Scholar 

  3. Finegold, S. M.: Anaerobic Infections and Their Therapy, presented at the Anaerobes Symposium, Brussels, Belgium, 17 September 1973.

  4. Mason, D. J., Dietz, A., DeBoer, C.: Lincomycin, a New Antibiotic. I. Discovery and Biological Properties, Antimicrob. Agents & Chemother. (1962) 554–559, 1963.

  5. Holloway, W. J., Kahlbaugh, R. A., Scott, E. G.: Lincomycin: A Clinical Study, Antimicrob. Agents Chemother. (1963) 200–203, 1964.

  6. Geddes, A. M., Sleet, R. A., Murdoch, J. McC. Lincomycin Hydrochloride: Clinical and Laboratory Studies, Brit. med. J. 2 (1964) 670–672.

    Google Scholar 

  7. Daikos, G. K., Kontomichalou, P., Papadoyannakis, N., Tourkantonis, A.: Clinical and Laboratory Experience with Lincomycin, Antimicrob. Agents Chemother. (1963) 197–199, 1964.

  8. Lewis, C., Clapp, H. W., Grady, J. E.: In Vitro and In Vivo Evaluation of Lincomycin, a New Antibiotic, Antimicrob. Agents Chemother. (1962) 570–582, 1963.

  9. MacLeod, A. J., Ross, H. B., Ozere, R. L., Digout, C., Van Rooyen, C. E. Lincomycin: A New Antibiotic Active Against Staphylococci and Other Gram-Positive Cocci: Clinical and Laboratory Studies, Can. Med. Assoc. J. 91 (1964) 1056–1060.

    Google Scholar 

  10. Finegold, S. M., Harada, N. E., Miller, L. G.: Lincomycin: Activity Against Anaerobes and Effect on Normal Human Fecal Flora, Antimicrob. Agents Chemother. (1965) 659–667, 1966.

  11. Kitamoto, O. Lincomycin: Its Dynamics and Clinical Effect. Symposium On Antibiotics. Supplement to the Bulletin of the Post-Graduate Committee in Medicine, The University of Sydney (Australia) 25 (1969) 34–55. (Symposium held September 12–14, 1966, Sydney, Australia).

    Google Scholar 

  12. Geddes, A. M., Munro, J. F., Murdoch, J. McC., Begg, K. J., Burns, B. A. Four Years Hospital Experience with Lincomycin Hydrochloride. Proceedings Fifth International Congress of Chemotherapy 1 (1967) 361–369.

    Google Scholar 

  13. Lerner, P. I.: Susceptibility of Actinomyces to Cephalosporins and Lincomycin, Antimicrob. Agents Chemotherapy (1967) 730–735, 1968.

  14. Blake, G. C. Sensitivities of Colonies and Suspensions of Actinomyces israelii to Penicillins, Tetracyclines, and Erythromycin, Brit. med. J. 1 (1964) 145–148.

    Google Scholar 

  15. Ingham, H. R., Selkon, J. B., Codd, A. A., Hale, J. H. A Study In Vitro of the Sensitivity to Antibiotics of Bacteroides fragilis, J. Clin. Path. 21 (1968) 432–436.

    Google Scholar 

  16. Lerner, P. I.: Susceptibility of Actinomyces Species to Lincomycin and Its Halogenated Analogues, Antimicrob. Agents Chemother. (1968) 461–464, 1969.

  17. Bornside, G. H., Cohn, I. Intestinal Antisepsis — Stability of Fecal Flora During Mechanical Cleansing, Gastroenterology 57 (1969) 569–573.

    Google Scholar 

  18. Mohr, J. A., Rhoades, E. R., Muchmore, H. G. Actinomycosis Treated with Lincomycin, JAMA 212 (1970) 2260–2262.

    Google Scholar 

  19. Thornton, G. F., Cramer, J. A.: Antibiotic Susceptibility of Bacteroides Species, Antimicrob. Agents Chemother. (1970) 509–513.

  20. Kislak, J. W. The Susceptibility of Bacteroides fragilis to 24 Antibiotics, J. Infect. Dis. 125 (1972) 295–299.

    Google Scholar 

  21. Tracy, O., Gordon, A. M., Moran, F., Love, W. C., Mc-Kenzie, P.: Lincomycins in the Treatment of Bacteroides Infections, Brit. med. J. (1972) 280–282.

  22. Geddes, A. M., Bridgewater, F. A. J., Williams, D. N., Oon, J., Grimshaw, G. J. Clinical and Bacteriological Studies with Clindamycin, Brit. med. J. 2 (1970) 703–704.

    Google Scholar 

  23. Dienes, I. The Isolation of L Type Cultures from Bacteroides with the Aid of Penicillin and Their Reversion into the Usual Bacilli, J. Bact. 56 (1948) 445–456.

    Google Scholar 

  24. Martin, W. J., Gardner, M., Washington, J. A. In Vitro Antimicrobial Susceptibility of Anaerobic Bacteria Isolated from Clinical Specimens. Antimicrob. Agents Chemother. 1 (1972) 148–158.

    Google Scholar 

  25. Duignan, N. M., Andrews, J., Williams, J. D. Pharmacological Studies with Lincomycin in Late Pregnancy, Brit. med. J. 3 (1973) 75–78.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Upjohn International Inc., Kalamazoo, Michigan, USA

    G. M. Savage

Authors
  1. G. M. Savage
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Savage, G.M. Lincomycin and clindamycin: Their role in chemotherapy of anaerobic and microaerophilic infections. Infection 2, 152–159 (1974). https://doi.org/10.1007/BF01642236

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01642236

Keywords

Search

Navigation